3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: GlobeNewswire
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials will be shared during Kidney Week 2025, the annual meeting of the American Society for Nephrology being held in Houston from November 5-9. ThursdayNovember 610 a.m. – 12 p.m.Convention CenterExhibit HallAbstract and Poster #TH-PO0227Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 3-Year Results from the PaTH Forward and PaTHway TrialsGosmanova, Schwarz,Rejnmark et alPresentation on November 6 by Dr. Elvira GosmanovaThe abstract is also available in the Journal of the American Society of Nephrology 36(10S):10.1681/ASN.20253ya
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of DirectorsPR Newswire
- Ascendis Pharma (ASND): Is There More Upside in the Valuation After Recent Momentum? [Yahoo! Finance]Yahoo! Finance
- How the FDA's TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- How Analyst Views Are Shifting the Ascendis Pharma Story After Recent Yorvipath and Pipeline Updates [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
ASND
Earnings
- 11/12/25 - Miss
ASND
Sec Filings
- 12/4/25 - Form 144
- 12/2/25 - Form 144
- 12/2/25 - Form 144
- ASND's page on the SEC website